Satsuma Pharmaceuticals — Technical Presentation (November 2022)
23 slides from Satsuma Pharmaceuticals's technical presentation, Nov 14, 2022
Slide 1: STS101 SUMMIT Phase 3 efficacy trial topline results
STS101 for the acute treatment of migraine SUMMIT Phase 3 efficacy trial topline results November 14, 2022 conference call Exhibit 99.2
Slide 2: Disclaimer
Disclaimer Important Notice This Presentation contains forward-looking statements concerning the business, operations and financial performance and condition of Satsuma Pharmaceuticals, Inc. (the “Company”), as well as the Company’s plans, objectives and expectations for its business operations and
Slide 3: Summary: STS101 (DHE nasal powder) and next steps
Large and growing multi-billion dollar market Summary STS101 (DHE nasal powder) Next steps 10/31/22 cash: $59.4M Developing innovative and differentiated treatment Satsuma does not plan to invest in commercializing STS101 We believe STS101 is approvable based on Ph1 and ASCEND results 40M U.S. preva
Slide 4: STS101 SUMMIT Phase 3 trial results
STS101 SUMMIT Phase 3 trial results
Slide 5: SUMMIT trial design
SUMMIT trial design R STS101 5.2 mg* Placebo* up to 30 days 56 days Within 10 days of treatment Screening Randomization & treatment End-of-study visit * All investigative product utilized improved, second-generation nasal delivery device (“Mk2”) End-of-study visit 1,591 subjects randomized Treat sin
Slide 6: Endpoint definitions
Endpoint definitions Patients report pain severity in electronic diary on a 4-point scale 0 No Pain 1 Mild Pain 2 Moderate Pain 3 Severe Pain SUMMIT subjects treated migraine attacks with Moderate or Severe Pain (i.e., rated as a “2” or “3”) immediately prior to treatment Pain free: Subject reports
Slide 7: Demographics & migraine history
Demographics & migraine history Subjects’ demographics and migraine history were representative of typical migraine patient population STS101 Placebo Age (mean; SD) 38.2 yrs (11.4) 38.9 yrs (11.5) Gender (% M/F) 21/79 20/80 Race (%) White African American Asian Other 82.5 12 3.5 2.0 81.4 13.7 3.4 1.
Slide 8: Patient disposition
Patient disposition STS101 Placebo Randomized 796 795 Modified Intent-to-Treat* 716 708 Safety** 731 729 *Subject treated qualifying migraine attack with study medication and has at least 1 post-treatment diary entry **Subject used study medication
Slide 9: Characteristics of treated migraine attacks
Characteristics of treated migraine attacks Note: Allodynia was considered present if subject had 2 positive responses in 6 question allodynia questionnaire immediately before study drug administration (Ashkenazi 2007; Tepper 2011) Symptoms just before treatment (% of subjects with symptom) STS101 P
Slide 10: Co-primary endpoints
Co-primary endpoints MBS: Most-bothersome symptom from among photophobia, phonophobia or nausea declared by subject at time of treated attack Subjects who took study medication, entered efficacy data at any timepoint, but did not report data at 2 hr were imputed to be treatment failures STS101 (n=71
Slide 11: Pain freedom over time (single dose)
Pain freedom over time (single dose) p=0.1661 p=0.0009 p<0.0001 p<0.0001 p<0.0001 p<0.0001 p=0.0004 STS101 was numerically superior to placebo at all but one time point (1h) Did not achieve statistical significance (p<0.05) at 2h Statistically significant at all time points after 2h Subjects who did
Slide 12: MBS freedom over time (single dose; no rescue medications)
MBS freedom over time (single dose; no rescue medications) p=0.0552 p=0.0002 p<0.0001 p<0.0001 p<0.0001 p<0.0001 p=0.0001 STS101 was numerically superior to placebo at all but one time point (0.5h) Did not achieve statistical significance (p<0.05) at 2h Statistically significant at all time points a
Slide 13: Pain relief over time (single dose; no rescue medications)
Pain relief over time (single dose; no rescue medications) p=0.0017 p<0.001 p<0.0001 p=0.0001 p<0.0001 p<0.0001 p=0.0003 STS101 was statistically significant vs placebo (p<0.05) at 2h and all time points thereafter Subjects who did not report data at a timepoint or who used any rescue medication pri
Slide 14: STS101 showed effects on key secondary endpoints
STS101 showed effects on key secondary endpoints Endpoint p-value Relief from Headache Pain at 2h post-dose (and all timepoints thereafter) 0.0017 (at 2h) Use of rescue medication within 24h and 48h post-dose 0.0001 Sustained freedom from Headache Pain from 2-24h post-dose (with no relapse or use of
Slide 15: Additional and potentially differentiating secondary endpoints
STS101 showed effects on additional and potentially differentiating secondary endpoints Endpoint p-value Free from pain at 4h (and all timepoints thereafter) in attacks with allodynia at time of treatment 0.022 (at 4h) Free from MBS at 4h (and all timepoints thereafter) in attacks with allodynia at
Slide 16: STS101 exhibited favorable safety and tolerability profile
STS101 exhibited favorable safety and tolerability profile STS101 Placebo Safety Population (n) 731 729 Treatment-Emergent Adverse Events reported by >1% of subjects Nasal discomfort 8.3% 1.5% Dysgeusia 3.7% 0.3% Nasal congestion 3.1% 0.8% Nausea 1.9% 0.7% Throat irritation 1.1% 0.3% Rhinorrhea 1.1%
Slide 17: Absolute efficacy rates comparable to gepants
STS101 showed absolute efficacy rates comparable to gepants STS101 / SUMMIT Gepant / Ph3 trials* Pain Free at 2h - Active 20.4% 19.2% – 21.8% Pain Free at 2h - Placebo 17.5% 11.8% - 14.3% MBS Free at 2h - Active 37.8% 35.1% - 38.8% MBS Free at 2h - Placebo 32.9% 25.2% - 27.7% However, placebo respon
Slide 18: Summary and conclusions
Summary and conclusions SUMMIT was a rigorously-conducted, large, placebo-controlled trial that addressed factors thought to contribute to previous EMERGE trial failing to achieve statistical significance on co-primary endpoints at 2h STS101 did not demonstrate statistical significance over placebo
Slide 19: Summary and conclusions
Summary and conclusions SUMMIT results suggest STS101 may have particular utility for people with migraine who experience: Attacks with allodynia Long-duration migraine attacks, including menstrually-associated migraine Nausea STS101 may be an attractive treatment option for patients who: Desire a l
Slide 20: STS101 program and plans
@atsuma pharmaceuticals STS101 program and plans
Slide 21: STS101 program and plans
STS101 program and plans STS101 is a differentiated asset Satsuma has established automated, commercial-scale manufacturing capability for STS101 Based on feedback from three meetings with FDA, Satsuma believes Phase 1 PK and ASCEND long-term, open-label safety trials will support NDA filing and pot
Slide 22: Next steps
Next steps Complete analysis of SUMMIT trial results Potential NDA filing (Q1 2023) Actively explore alternatives to maximize value for shareholders Minimize cash expenditures
Slide 23: Thank you
@atsuma pharmaceuticals Thank you
Satsuma Pharmaceuticals — Technical Presentation (November 2022) on 6ix